Complex therapy recovered after infectious diseases

ABSTRACT

Introduction. At the present time, the incidence of acute respiratory viral infections (ARVI) remains at a high level. Some patients who have undergone ARVI and COVID-19 have been disturbed by astheno-neurotic syndrome and chronic fatigue syndrome for quite a long time. Aim. To study the efficacy and safety dietary supplement treatment in the rehabilitation of patients recovered after acute respiratory viral infections. Materials and methods. We have examined 50 patients diagnosed with acute respiratory viral infections (38 people) and COVID-19 (12 people). Age of patients from 25 years to 60 years old, average age 35 ± 11.84 years old. All patients were randomized into two study groups the first group (25 people) received a biologically active food supplement and the second group (25 people) did not receive such complex. Сomplex was prescribed to the participants of the first group in amount of two capsules once a day. The course of therapy was 14 days. Before and after taking, all patients were assessed for shortness of breath on the MRC scale, depression on the Beck scale, chronic fatigue syndrome on the FAS scale, and the level of C-reactive protein (CRP) was assessed as well. Results. In the course of the observation, no significant difference between the groups was recorded in the dynamics of the state of assessment for dyspnea, depression and hemoglobin level. The average level of CRP before taking in the first group was 4.4 mg/l (from 0 to 22 mg/l), in the second – 3.8 mg/l (from 0 to 14 mg/l). When comparing the dynamics in the first group, there was more pronounced decrease in the level of CRP. In the first group, decrease in manifestations of pathological fatigue was revealed, characterized by decrease in FAS scores compared to the control group, where the number of scores, on the contrary, increased. Conclusions. Сomplex has a corrective effect on astheno-neurotic symptoms after suffering from acute respiratory viral infections or post-COVID syndrome. © 2022, Remedium Group Ltd. All rights reserved.